Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life
about
Neovascular age-related macular degeneration treated with ranibizumab or aflibercept in the same large clinical setting: visual outcome and number of injections.Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland.VISUAL ACUITY IMPROVEMENT WHEN SWITCHING FROM RANIBIZUMAB TO AFLIBERCEPT IS NOT SUSTAINED.Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context.Three-month outcome of intravitreal ziv-aflibercept in eyes with diabetic macular oedema.
P2860
Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life
@ast
Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life
@en
type
label
Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life
@ast
Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life
@en
prefLabel
Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life
@ast
Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life
@en
P2093
P2860
P1433
P1476
Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life
@en
P2093
Andri Signorell
Jeremy P Howell
Livia Faes
Lucas M Bachmann
Mario Bittner
Martin K Schmid
Michael A Thiel
Oliver Reich
Sophie C Boehni
P2860
P304
P356
10.1371/JOURNAL.PONE.0135050
P407
P577
2015-08-04T00:00:00Z